|Articles|June 17, 2010
QUMAS Launches Highly Scalable Enterprise Compliance Solution for Microsoft SharePoint 2010
Advertisement
QUMAS' domain knowledge will now be available on a SharePoint 2010 platform.
"We have been approached by a number of firms that intend to make SharePoint 2010 a cornerstone of their technology infrastructure," said Kevin O'Leary, CEO QUMAS. " We recognize the game changing impact that SharePoint is having on the technology landscape. This is the single most exciting initiative we have undertaken in our 16 years of business and we are delighted to be working with Microsoft to deliver a compliance solution built entirely on the SharePoint 2010 platform."
The QUMAS Compliance Solution adds key solution-specific functionality that leverages and extends the underlying SharePoint platform to support industry demands in a number of key areas. These will include:
-Manufacturing Controlled Documents
-CAPA's and Deviations
-Clinical Trial Management
-Regulatory Documentation
-SOP Management (Policies and Procedures)
-Customer Complaints
-Change Control
-Policy Training and Certification
-R&D Document Control
-Manufacturing Controlled Documents
-CAPA's and Deviations
-Clinical Trial Management
-Regulatory Documentation
-SOP Management (Policies and Procedures)
-Customer Complaints
-Change Control
-Policy Training and Certification
-R&D Document Control
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Phase III BRUIN CLL-313 Trial Finds Jaypirca Extends Progression-Free Survival in Treatment-Naïve CLL/SLL
2
Latest NIMBLE Study Results Highlight Progress in gMG Research
3
ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
4
Q&A: Strategies for Successful Global Clinical Trial Delivery
5